RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Starpharma Holdings Stock

Starpharma Holdings Stocks 2025

Starpharma Holdings Stocks

411.43 M

Ticker

SPL.AX

ISIN

AU000000SPL0

WKN

796461

In 2025, Starpharma Holdings had 411.43 M outstanding stocks, a 0% change from the 411.43 M stocks in the previous year.

The Starpharma Holdings Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
2025e411.43
2024411.43
2023409.04
2022406.9
2021396.88
2020372.23
2019371.29
2018370.14
2017368.16
2016345.04
2015310.14
2014284.41
2013283.28
2012267.65
2011242.56
2010225.55
2009184.08
2008177.99
2007161.67
2006132.3
2005111.24

Starpharma Holdings shares outstanding

The number of shares was Starpharma Holdings in 2024 — This indicates how many shares 411.433 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Starpharma Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Starpharma Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Starpharma Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Starpharma Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Starpharma Holdings Aktienanalyse

What does Starpharma Holdings do?

Starpharma Holdings Ltd is an Australian company specializing in the development of innovative solutions in the fields of pharmacy and biotechnology. The company was founded in 1996 and has since written an impressive history full of successful developments and numerous partnerships. The main business of Starpharma focuses on the development and commercialization of drugs and other health products based on dendrimer technology. One of the most advanced applications of dendrimer technology is VivaGel, a topical gel for the prevention of sexually transmitted diseases, particularly HPV (Human Papillomavirus). VivaGel is based on a dendrimer that acts both as an antiviral agent and an antibiotic, capable of preventing infection by different types of HPV. The product has already undergone Phase III clinical trials and is currently being marketed worldwide. In addition to VivaGel, Starpharma also offers dendrimer-based technologies and services in the field of drug development. The company has formed numerous partnerships with major pharmaceutical companies such as AstraZeneca, GSK, and Merck, and is involved in the development of drugs for cancer, autoimmune diseases, and infectious diseases. Furthermore, Starpharma has expanded its dendrimer technology to other industries, such as agriculture, where dendrimers can contribute to improving soil quality and reducing pesticide use. In this sector, Starpharma has also formed partnerships with agricultural companies such as Adama and Nufarm. Overall, Starpharma is a company that has experienced significant growth in recent years and continues to focus on the development of new and innovative products and solutions. Its core competence in dendrimer technology has allowed it to establish itself as a key player in various industries and build numerous partnerships with global companies. With its diverse range of products and services and a strong focus on research and development, Starpharma can be considered an important player in the field of biotechnology and healthcare innovations. Indicate the sector in starpharma specialize in. Starpharma Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Starpharma Holdings's Shares Outstanding

Starpharma Holdings's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Starpharma Holdings’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Starpharma Holdings’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Starpharma Holdings’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Starpharma Holdings stock

How many stocks are there of Starpharma Holdings?

The current number of stocks of Starpharma Holdings is 411.43 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Starpharma Holdings are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Starpharma Holdings evolved in recent years?

The number of shares of Starpharma Holdings has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Starpharma Holdings as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Starpharma Holdings?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Starpharma Holdings pay?

Over the past 12 months, Starpharma Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Starpharma Holdings is expected to pay a dividend of 0 AUD.

What is the dividend yield of Starpharma Holdings?

The current dividend yield of Starpharma Holdings is .

When does Starpharma Holdings pay dividends?

Starpharma Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Starpharma Holdings?

Starpharma Holdings paid dividends every year for the past 0 years.

What is the dividend of Starpharma Holdings?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Starpharma Holdings located?

Starpharma Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Starpharma Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Starpharma Holdings from 7/1/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 7/1/2025.

When did Starpharma Holdings pay the last dividend?

The last dividend was paid out on 7/1/2025.

What was the dividend of Starpharma Holdings in the year 2024?

In the year 2024, Starpharma Holdings distributed 0 AUD as dividends.

In which currency does Starpharma Holdings pay out the dividend?

The dividends of Starpharma Holdings are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Starpharma Holdings

Our stock analysis for Starpharma Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Starpharma Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.